AstraZeneca Hears CAT’s Meow With Biotech Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal for Cambridge Antibody Technology, valued at $1.07 bil., will shift focus of AstraZeneca’s pipeline.
You may also be interested in...
Deals Of The Week: Pfizer Leads The Action Even After Wyeth Purchase
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Deals Of The Week: Pfizer Leads The Action Even After Wyeth Purchase
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
MedImmune Appoints Development Leadership Team
Former Cambridge Antibody Technology exec to oversee product development.